glp-1 roche Ad hoc announcement pursuant to Art. 53 LR] announces positive Phase I results of its oral receptor agonist CT-996 for the treatment of people with obesity When doses were increased rapidly
Pay in 4 interest-free payments of $6.67 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Nov 17 - Nov 22
![glp-1 roche Ad hoc announcement pursuant to Art. 53 LR] announces positive Phase I results of its oral receptor agonist CT-996 for the treatment of people with obesity When doses were increased rapidly](https://www.swissinfo.ch/content/wp-content/uploads/sites/13/2026/04/676660337_highres.jpg?ver=87581e01)
![glp-1 roche Ad hoc announcement pursuant to Art. 53 LR] announces positive Phase I results of its oral receptor agonist CT-996 for the treatment of people with obesity When doses were increased rapidly](https://static.biospace.com/dims4/default/7c8a734/2147483647/strip/false/crop/3803x2139+0+239/resize/1200x675!/quality/90/?url=https%3A%2F%2Fk1-prod-biospace.s3.us-east-2.amazonaws.com%2Fbrightspot%2F68%2Fb4%2Ff13d76df42619d636b92913eb589%2Fistock-804989330.jpg)
![glp-1 roche Ad hoc announcement pursuant to Art. 53 LR] announces positive Phase I results of its oral receptor agonist CT-996 for the treatment of people with obesity When doses were increased rapidly](https://hips.hearstapps.com/hmg-prod/images/8b89e94a-dad2-454f-a45f-3ed3b6be1419.png?crop=0.888888888889xw:1xh;center,top&resize=1200:*)





















